Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

• Published in: American journal of hematology 2015-04, Vol.90 (4), p.282-287
• Main Authors: Iriyama, Noriyoshi, Fujisawa, Shin, Yoshida, Chikashi, Wakita, Hisashi, Chiba, Shigeru, Okamoto, Shinichiro, Kawakami, Kimihiro, Takezako, Naoki, Kumagai, Takashi, Inokuchi, Koiti, Ohyashiki, Kazuma, Taguchi, Jun, Yano, Shingo, Igarashi, Tadahiko, Kouzai, Yasuji, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl - biosynthesis; Fusion Proteins, bcr-abl - genetics; Hematology; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Male; Medical research; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; RNA, Messenger - biosynthesis; RNA, Neoplasm - biosynthesis; ROC Curve; Thiazoles - administration & dosage; Thiazoles - adverse effects; Thiazoles - therapeutic use; Time Factors; Transcription, Genetic; Young Adult
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.23923

To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic‐phase chronic myeloid leukemia (CML‐CP), we performed a clinical trial named the “D‐First study.” Fifty‐two patients with newly diagnosed CML‐CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as